ProCE Banner Activity


Current and Emerging Therapeutic Advances in Follicular Lymphoma: A Class in Session

Text Module

Review expert perspectives on new and emerging immunotherapeutic approaches for the treatment of patients with relapsed/refractory follicular lymphoma.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: March 06, 2023

Expiration: March 05, 2024

No longer available for credit.



John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Jean Louise Koff

Jean Louise Koff, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Target Audience

This educational program is intended for HCPs who are involved in the treatment of patients with FL, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Program Learning Goal

The goal of this activity is to improve knowledge, enhance competence, and advance the quality of performance of HCPs treating patients with FL by leveraging recent and emerging data that must be considered in treatment decisions.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the current evidence to support novel immunotherapeutic approaches for patients with FL

  • Select treatment regimens for patients with FL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes

  • Identify patients with FL who would likely benefit from enrollment on a clinical trial

  • Manage adverse events (AEs) associated with newer therapeutic regimens used in the treatment of FL


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

John M. Burke, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Epizyme, Kura, Kymera, MorphoSys, Novartis, Nurix, Roche/Genentech, Seattle Genetics, TG Therapeutics, Verastem, X4 Pharmaceuticals; researcher: MorphoSys; speaker’s bureau: BeiGene, Seattle Genetics.

Jean L. Koff, MD, MSc: consultant: BeiGene, Janssen/Pharmacyclics, Gamida Cell, MorphoSys, TG Therapeutics; researcher: Atara, Celgene, Janssen/Pharmacyclics, Oncternal, Viracta.

The planners and content peer reviewers from Clinical Care Options, LLC do not have an relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 06, 2023, through March 05, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-075-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.